Since both HIV and HCV are known to be highly variable and infections are treated with combination therapies that target different viral proteins, random amplification followed by next-generation sequencing could be an attractive alternative to Sanger sequencing for obtaining complete viral genomes. Moreover, one experimental approach could enable the simultaneous mapping of virus and human origin sequence reads, which is of particular interest for the detection of single nucleotide polymorphisms (SNPs) associated with disease progression and treatment response. A plasma sample obtained from a patient infected with HIV-1 recombinant subtype B and F1, and diagnosed with AIDS; and another sample from an HCV infected patient who progressed to fibrosis stage F1 were included in this pilot study. They were both characterized by a high viral load, i.e. \>10M copies/ml for HIV and \>3.5M IU/ml for HCV. Samples were directly extracted or pre-treated with homogenisation, centrifugation and filtration. Subsequently, purified nucleic acids were subjected to targeted (HIV-1 PR-RT and HCV NS3 protease) amplification and Sanger sequencing, or to random amplification followed by Illumina sequencing (∼2M paired end reads attributed to each sample). Quality of the Illumina reads was checked using FastQC, followed by a *de novo* assembly of sample-specific contigs using the VICUNA and V-FAT software packages. In total, 0.3% (*n* = 5557) and 0.02% (*n* = 421) of the reads mapped to the HCV genome, respectively with or without virus enrichment steps. This sufficed for the *de novo* generated contigs to cover 98.3 and 51.3% of the HCV genome with and without pre-treatment steps, respectively. Lower numbers of reads could be mapped for HIV-1 (821 versus 196 without virus enrichment), resulting in only 45.6 and 21.7% coverage of the full-genome. For both samples, the number of reads (\<2M) was too low to map SNPs of interest within the human genome. Subject to adaptations in the protocol, such as improved enrichment strategies and deeper sequencing, this approach could be suitable for the surveillance of local HIV-1 and HCV epidemics. More extensive studies are required to investigate its usefulness in clinical research.
